US demand to reach $7.4 billion in 2008
US demand for vaccines will advance 8.6 percent per annum to $7.4 billion in 2008. Several factors will underlie growth, including an increasing emphasis on prevention in human and veterinary medicine, the commercialization of new and improved products, the upgrading of defense systems against bioterrorism, the expansion of infant and child health care programs, aging demographic trends, the strengthening of food safety regulations, rising pet ownership, and a greater availability of pet health insurance.
Pediatric preparations to remain dominant human vaccine
Pediatric preparations will remain the top-selling group of vaccines due to well-established safety and effectiveness criteria, improving product formulations and a large number of potential new patients. About 40 percent of US children are not fully immunized in line with recommended schedules advocated by the Centers for Disease Control and Prevention and other medical organizations. Attempts to extend coverage to a larger percentage of children will benefit growth opportunities for pediatric vaccines, especially RSV, pneumococcal, DTaP, measles-mumps-rubella and varicella preparations.
Based on a large potential patient base, hepatitis preparations will continue to generate the second-largest sales volume among vaccines. However, unfavorable demographic trends will temper hepatitis A vaccine. A decreasing number of unvaccinated adults, attributable largely to the previous immunization of health care workers, will soften growth in demand for hepatitis B vaccines.
Biodefense vaccines, consisting of preparations against anthrax and smallpox, will sustain moderate gains in demand over the next several years as the ongoing threat of bioterrorism prompts the government to build and maintain supplies. With annual shots recommended for most of the population and new formulations extending product availability, influenza vaccines will generate strong long-term growth opportunities. The anticipated introduction of new vaccines for SARS will underlie the above average sales gains projected for travel vaccines.
AIDS, cancer vaccines to bolster long-term prospects
New product introductions against an expanding range of disease targets will represent the key force leading to rapid growth opportunities for other human vaccines. Within the next half decade, advances in biotechnology and related life science disciplines are expected to bring the first vaccines for AIDS, cancer, herpes and West Nile virus into the US marketplace. By 2013, several additional vaccines will be approved for the prevention of these diseases, contributing vast improvements to national health and living standards.
Veterinary vaccines showing market maturity
Growth in veterinary vaccines demand will lag the pace of human vaccines due to greater market maturity; more limited opportunities to develop new, large-selling products; and ongoing safety controversies. More favorably, advances in biotechnology and related life science fields will lead to the introduction of improved preparations for a number of high value-added niche applications. The market for veterinary vaccines will continue to be divided between products that promote food safety and products indicated for maintaining the health and wellness of companion animals.
Study coverage
This new Freedonia study, Vaccines, presents historic US demand data through 2003 plus forecasts to 2008 and 2013 for human and veterinary vaccines by type. The study also examines the US market environment, reviews principal vaccine technologies, details industry structure, presents company market share data and profiles 25 leading industry competitors.
TABLE OF CONTENTS
INTRODUCTION
I. EXECUTIVE SUMMARY
II. MARKET ENVIRONMENT
- General
- Economic Factors
- Recent Economic Trends
- Long-Term Economic Projections
- Demographic Patterns
- Diseases & Disorders
- Medical Conditions
- Acute Conditions
- Chronic Conditions
- Specified Reportable Diseases
- AIDS
- Lyme Disease
- Varicella
- Tuberculosis
- Pertussis
- Hepatitis
- Other Specified Reportable Diseases
- Health Care Trends
- Health Insurance & Reimbursement Trends
- National Health Expenditures
- Medical Providers
- Patient Procedures
- Veterinary Health Care
- Veterinary Demographic Trends
- Veterinarians
- Veterinary Health Expenditures
III. VACCINE TECHNOLOGIES
- General
- Component Vaccines
- Biotechnology-Derived Vaccines
- Recombinant DNA
- (continued on next page)
- Monoclonal Antibodies
- Vector Systems
- Live Vaccines
- Killed Bacterial & Viral Vaccines
IV. PRODUCT OVERVIEW
- General
- Major Product Groups
- Human Vaccines
- Veterinary Vaccines
- Market Trends
- Regulatory Considerations
- Human Vaccine Regulation
- Veterinary Vaccine Regulation
- US Trade
- International Markets
- North America
- Western Europe
- Asia/Pacific
- Other International Markets
V. HUMAN VACCINES
- General
- Pediatric Vaccines
- RSV Antibodies
- Pneumococcal Vaccines
- DTaP Vaccines
- Measles-Mumps-Rubella (M-M-R) Vaccines
- Varicella Vaccines
- Polio Vaccines
- Haemophilus b Vaccines
- Other Pediatric Vaccines
- Hepatitis Vaccines
- Hepatitis B Vaccines
- Hepatitis A Vaccines
- Other Hepatitis Vaccines
- Biodefense Vaccines
- Smallpox Vaccines
- Anthrax Vaccines
- Other Biodefense Vaccines
- Botulinum
- Brucellosis
- Plague
- Q Fever
- Ricin
- Tularemia
- Influenza Vaccines
- Travel Vaccines
- Encephalitis Vaccines
- Rabies Vaccines
- SARS Vaccines
- Other Travel Vaccines
- Typhoid Fever
- Yellow Fever
- Dengue Fever
- Malaria
- Cholera
- Other Human Vaccines
- Meningococcal Vaccines
- BCG Vaccines
- Developmental Vaccines
- Cancer Vaccines
- AIDS Vaccines
- Herpes Vaccines
- West Nile Vaccines
- Other Developmental Vaccines
VI. VETERINARY VACCINES
- General
- Livestock Vaccines
- Bovine Vaccines
- Swine Vaccines
- Ovine Vaccines
- (continued on next page)
- Companion Animal Vaccines
- Canine Vaccines
- Feline Vaccines
- Equine Vaccines
- Poultry Vaccines
- Other Veterinary Vaccines
VII. INDUSTRY STRUCTURE
- General
- Market Share
- Competitive Strategies
- Mergers & Acquisitions
- Licensing & Related Agreements
- Research & Development
- Manufacturing
- Marketing & Distribution
- Company Profiles
- Acambis plc
- Akzo Nobel NV
- Avecia Group plc
- Aventis SA
- AVI BioPharma Incorporated
- Baxter International Incorporated
- Berna Biotech Limited
- Berna Products Corporation, see Acambis plc
- Biogen Idec Incorporated
- BioProtein Technologies
- CancerVax Corporation
- Chiron Corporation
- Covalent Group Incorporated
- Dow Chemical Company
- DynPort Vaccine Company LLC
- Fort Dodge Animal Health, see Wyeth
- GenVec Incorporated
- Genzyme Corporation
- GlaxoSmithKline plc
- (continued on next page)
- Intervet Incorporated, see Akzo Nobel NV
- Large Scale Biology Corporation
- MedImmune Incorporated
- Merck & Company Incorporated
- Merial Limited
- Nobilon, see Akzo Nobel NV
- Pevion Biotech Limited, see Berna Biotech Limited
- Pfizer Incorporated
- PowderJect Pharmaceuticals plc, see Chiron Corporation
- VaxGen Incorporated
- VaxInnate Corporation
- Wyeth
LIST OF TABLES
SECTION I -- EXECUTIVE SUMMARY
- Summary Table
SECTION II -- MARKET ENVIRONMENT
- 1 Macroeconomic Indicators
- 2 Demographic Indicators
- 3 Acute Conditions by Type
- 4 Chronic Conditions by Type
- 5 Specified Reportable Diseases
- 6 National Health Expenditures by Type
- 7 Medical Providers by Type
- 8 Patient Procedures by Type
- 9 Veterinary Health Care Indicators
- 10 Veterinary Health Expenditures
SECTION III -- VACCINE TECHNOLOGIES
- 1 Vaccine Demand by Technology
SECTION IV -- PRODUCT OVERVIEW
- 1 Vaccines Demand by Major Product Group
- 2 Human Vaccines Licensed for US Sale
- 3 Vaccines -- Market Trends, 1993-2003
- 4 US Trade in Vaccines
- 5 World Vaccines Demand by Country/Region
- 6 Western Europe -- Vaccines Demand by Type & Selected Countries
SECTION V -- HUMAN VACCINES
- 1 Human Vaccines Demand
- 2 Pediatric Vaccines Demand by Type
- 3 RSV Antibodies Demand
- 4 Pneumococcal Vaccines Demand
- 5 DTaP (Diphtheria, Tetanus, Pertussis) Vaccines Demand
- 6 M-M-R (Measles-Mumps-Rubella) Vaccines Demand
- 7 Varicella Vaccines Demand
- 8 Polio Vaccines Demand
- 9 Haemophilus b (Hib) Vaccines Demand
- 10 Rotavirus Vaccines Demand
- 11 Hepatitis Vaccines Demand
- 12 Hepatitis B Vaccines Demand
- 13 Hepatitis A Vaccines Demand
- 14 Other Hepatitis Vaccines Demand
- 15 Biodefense Vaccines Demand
- 16 Smallpox Vaccines Demand
- 17 Anthrax Vaccines Demand
- 18 Other Biodefense Vaccines Demand
- 19 Influenza Vaccines Demand
- 20 Travel Vaccines Demand by Type
- 21 Encephalitis Vaccines Demand
- 22 Rabies Vaccines Demand
- 23 SARS Vaccines Demand
- 24 Other Travel Vaccines Demand
- 25 Other Human Vaccines Demand by Type
- 26 Meningococcal Vaccines Demand
- 27 BCG Vaccines Demand
- 28 Developmental Vaccines by Type
- 29 Cancer Vaccines Demand by Type
- 30 AIDS Vaccines Demand
- 31 Herpes Vaccines Demand
- 32 West Nile Virus Vaccines Demand
- 33 Other Developmental Vaccines Demand
SECTION VI -- VETERINARY VACCINES
- 1 Veterinary Vaccines Demand by Product Group
- 2 Livestock Vaccines Demand by Type
- 3 Companion Animal Vaccines Demand by Type
- 4 Poultry Vaccines Demand
- 5 Other Veterinary Vaccines Demand
SECTION VII -- INDUSTRY STRUCTURE
- 1 US Vaccine Revenues by Company, 2003
- 2 Selected Acquisitions & Divestitures
- 3 Selected Cooperative Agreements
LIST OF CHARTS
SECTION III -- VACCINE TECHNOLOGIES
- 1 Vaccines Demand by Technology, 2003
SECTION IV -- PRODUCT OVERVIEW
- 1 Vaccines Demand by Major Product Group, 2003
- 2 Recommended Childhood & Adolescent Immunization - United States, 2001
SECTION V -- HUMAN VACCINES
- 1 Human Vaccines Demand by Type, 2003
SECTION VI -- VETERINARY VACCINES
- 1 Veterinary Vaccines Demand by Type, 2003
SECTION VII -- INDUSTRY STRUCTURE
- 1 Human Vaccines US Market Share by Company, 2003
- 2 Veterinary Vaccines US Market Share by Company, 2003
